Oncomatryx Biopharma S.L.
Oncomatryx is a pioneering biotech company focused on modulating the tumor microenvironment to develop innovative treatments for aggressive metastatic solid tumors. With a mission to transform cancer therapy, they develop precision drugs targeting cancer-associated fibroblasts and other components of the tumor microenvironment. Their approach involves advanced antibody-drug conjugates (ADCs) and a focus on personalized medicine to improve patient outcomes and aim for a future where cancer can be cured.
Industries
Nr. of Employees
small (1-50)
Oncomatryx Biopharma S.L.
Parque Tecnológico de Bizkaia 801B – 2P, 48160 Derio. Bizkaia. SPAIN
Patents
Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
US-9993567-B2
View DetailsMethods and products for in vitro diagnosis, in vitro prognosis and the development of drugs against invasive carcinomas
US-9702879-B2
View DetailsComposition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
US-8444983-B2
View Details
Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
US-9993567-B2
View DetailsMethods and products for in vitro diagnosis, in vitro prognosis and the development of drugs against invasive carcinomas
US-9702879-B2
View DetailsComposition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
US-8444983-B2
View DetailsProducts
FAP-targeting antibody–drug conjugate (clinical-stage)
A clinical-stage ADC designed to target fibroblast activation protein (FAP) on cancer-associated fibroblasts to deliver a synthetic cytotoxic payload; evaluated in preclinical models and in early-phase clinical trials for metastatic solid tumors.
IHC assay for COL11A1 (companion diagnostic)
An immunohistochemistry tissue-staining assay for detection of COL11A1 in biopsy samples, intended to diagnose and prognose invasive tumors and to support patient selection for stroma-targeted therapies.
FAP-targeting antibody–drug conjugate (clinical-stage)
A clinical-stage ADC designed to target fibroblast activation protein (FAP) on cancer-associated fibroblasts to deliver a synthetic cytotoxic payload; evaluated in preclinical models and in early-phase clinical trials for metastatic solid tumors.
IHC assay for COL11A1 (companion diagnostic)
An immunohistochemistry tissue-staining assay for detection of COL11A1 in biopsy samples, intended to diagnose and prognose invasive tumors and to support patient selection for stroma-targeted therapies.
Services
Clinical development services for first-in-human and dose-escalation oncology studies, including protocol implementation, multicenter site coordination and combination cohorts with standard therapies or immunotherapies.
End-to-end discovery services for stromal-targeted ADCs including target validation, antibody generation, payload selection, conjugation strategy and in vivo efficacy testing in PDX and humanized models.
Development, optimization and multicenter validation of IHC assays for stromal biomarkers to support patient selection and prognosis.
Clinical development services for first-in-human and dose-escalation oncology studies, including protocol implementation, multicenter site coordination and combination cohorts with standard therapies or immunotherapies.
End-to-end discovery services for stromal-targeted ADCs including target validation, antibody generation, payload selection, conjugation strategy and in vivo efficacy testing in PDX and humanized models.
Development, optimization and multicenter validation of IHC assays for stromal biomarkers to support patient selection and prognosis.
Expertise Areas
- Tumor microenvironment targeting
- Antibody-drug conjugate (ADC) development
- Preclinical oncology models (PDX, humanized mice)
- Early-phase clinical trial management (Phase I/II)
Key Technologies
- Antibody-drug conjugates (ADCs)
- Monoclonal antibody engineering
- Synthetic tubulysin-analog payloads
- Linker and conjugation chemistry
News & Updates
Oncomatryx announced a capital increase of 15 million euros to start clinical trials in Spain and the US for their drugs targeting the tumor microenvironment.
Oncomatryx acquired Tube Pharmaceuticals GmbH, enhancing its pipeline of ADCs targeting the tumor microenvironment.
Oncomatryx successfully raised €25 million to fund Phase Ib-II trials of OMTX705, a first-in-class ADC targeting FAP.
Oncomatryx will present results of a clinical trial for metastatic tumors of colon, pancreas, and lung.
Oncomatryx will present clinical trial results for metastatic tumors of colon, pancreas, and lung.
Oncomatryx received regulatory approval for its investigational new drug application for OMTX705, targeting the tumor microenvironment.
Oncomatryx announced a capital increase of 15 million euros to start clinical trials in Spain and the US for their drugs targeting the tumor microenvironment.
Oncomatryx acquired Tube Pharmaceuticals GmbH, enhancing its pipeline of ADCs targeting the tumor microenvironment.
Oncomatryx successfully raised €25 million to fund Phase Ib-II trials of OMTX705, a first-in-class ADC targeting FAP.
Oncomatryx will present results of a clinical trial for metastatic tumors of colon, pancreas, and lung.
Oncomatryx will present clinical trial results for metastatic tumors of colon, pancreas, and lung.
Oncomatryx received regulatory approval for its investigational new drug application for OMTX705, targeting the tumor microenvironment.